Common chronic conditions such as hypertension, coronary heart disease, diabetes, cognitive impairment, hyperlipidaemia, chronic kidney disease and Parkinson’s disease
Conditions
Interventions
treatment group:Yuze skin barrier body lotion application
control group:blank,no intervention
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
55 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. A signed and dated informed consent form; 2. Commitment to comply with research procedures and cooperate throughout the entire research process; 3. Age >= 55 years; 4. Able to understand all aspects of this trial independently or with the help of a trusted person; 5. Plan to reside locally for >= 3 years; 6. History of at least one confirmed chronic disease in past or present: 1) Hypertension: systolic blood pressure >= 140 mmHg and/or diastolic blood pressure >= 90 mmHg; 2) Diabetes: according to 1999 WHO criteria, fasting blood glucose >= 7.0 mmol/L, or already clearly diagnosed with diabetes; 3) Hyperlipidemia: total cholesterol TC >= 6.2 mmol/L, or triglycerides TG >= 2.3 mmol/L, or high-density lipoprotein cholesterol HDL-C = 4.1 mmol/L; 4) Chronic kidney disease: defined as estimated glomerular filtration rate eGFR = 50%; 6) Cognitive impairment: determined by a score >= 1 on the Clinical Dementia Rating (CDR) Simplified Chinese version; 7) Parkinson's disease: presence of bradykinesia is required, along with at least one of the following: a. Resting tremor with 4–6 Hz frequency; b. Muscle rigidity. 7. Able to complete skin barrier function measurements; 8. Routine annual physical examination items, and agree to authorize access to physical examination information.
Exclusion criteria
Exclusion criteria: 1.Known allergy to the investigational product; 2.Active severe skin diseases (impetigo, severe psoriasis, etc.); 3.accepted systemic immunosuppressive or anti-inflammatory therapy within 1 month; 4.Severe end-stage diseases (terminal cancer, severe heart failure, dialysis, etc.); 5.Other unsuitable conditions assessed by the investigator?
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TEWL;DBP;SBP;C-peptide; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin count;TC;eGFR;Mean Hemoglobin;Red blood cell distribution width;Mean corpuscular hemoglobin concentration;Percentage of neutrophils;Corneometer;Free thyroxine FT4;Lymphocyte percentage;FBG;Heart rate;Free triiodothyronine FT3;SebumScale;TG;INS;Geriatric Depression Scale Score;White blood cell count;HbA1c;weight;Thyroid-stimulating hormone TSH;Montreal Cognitive Assessment;Auditory Verbal Learning Test;Pittsburgh Sleep Quality Index;Creatinine;Plateletcrit;Adverse Record;Medical history including medication records;Hematocrit;IL-1;Uric acid;HDL-C;IL-6;Urea nitrogen;Platelet count;hs-CRP;LDL-C; | — |
Countries
China
Contacts
Public ContactXia Li
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed